Teva Pharmaceutical Industries Limited ( NYSE: TEVA) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Richard D. Francis - President, CEO & Director ...

NORTHAMPTON, MA / ACCESS Newswire / June 10, 2025 / Teva Pharmaceuticals has been recognized with the 2025 Power of ...

Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Teva Pharmaceutical Industries Limited - Depositary ...

A Relative Strength Rating upgrade for Teva Pharmaceutical ADR shows improving technical performance. Will it continue?

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

In 2020, we committed to launching eight Access to Medicines programs by 2025, aimed at providing treatments to underserved ...

Teva got more time to ask the Supreme Court to review a ruling that could strip hundreds of drug patents from a key FDA registry, a decision the company says could reshape how makers of brand-name ...

SDZNY, TEVA, and VTRS show resilience with strong biosimilar pipelines and margin strategies amid industry headwinds.

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's ...

Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® ...

Investing.com -- Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva ...